


RealRate

PHARMACEUTICAL 2018

Cocrystal Pharma Inc. Rank 27 of 349







RealRate

PHARMACEUTICAL 2018

## Cocrystal Pharma Inc. Rank 27 of 349

The relative strengths and weaknesses of Cocrystal Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cocrystal Pharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Cocrystal Pharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 443% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	2,176
Cost of Goods Sold	0
Intangible Assets	65,195
Liabilities, Current	1,406
Liabilities, Non-Current	14,620
Other Assets	53,936
Other Compr. Net Income	0
Other Expenses	-6,880
Other Liabilities	0
Other Net Income	769
Property and Equipment	119
Research and Development	5,822
Revenues	0
Selling, General and Administrative Expense	2,440

Output Variable	Value in 1000 USD
Assets	121,426
Liabilities	16,026
Expenses	1,382
Stockholders Equity	105,400
Net Income	-613
Comprehensive Net Income	-613
Economic Capital Ratio	165%

